EverSource Wealth Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

EverSource Wealth Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-79	Closed	-$3.55K	–	3156
2024 Q2	$3.55K	Buy	79 +7	+10%	+$292	﹤0.01%	2341
2024 Q1	$3.07K	Buy	72 +2	+3%	+$84	﹤0.01%	2236
2023 Q4	$2.97K	Buy	+70	New	+$2.01K	﹤0.01%	2059

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

EverSource Wealth Advisors's CERE Position: Q3 2024 in Review

EverSource Wealth Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 79 shares — an estimated $3.55K sold.

EverSource Wealth Advisors first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $3.55K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

EverSource Wealth Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
EverSource Wealth Advisors sold 79 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.55K.
EverSource Wealth Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
EverSource Wealth Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.55K in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on EverSource Wealth Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.